AstraZeneca is trading 4.41% up at $169.17, with its AI drug-discovery collaboration with insitro the clearest company-specific catalyst.
- The collaboration targets potential treatments for difficult-to-treat liver and heart diseases; terms include $40 million upfront, up to approximately $1.46 billion in milestone payments, plus royalties.
- Shares closed at $162.03 on October 14, up 3.99%, before further gains in the live current session; no reliable volume information was provided.